Activation and function of cyclin T-Cdk9 (positive transcription elongation factor-b) in cardiac muscle-cell hypertrophy

Nature Medicine

Volumn 8, Issue 11, 2002, Pages 1310-1317

  Sano, Motoaki ^a   Abdellatif, Maha ^b   Oh, Hidemasa ^a   Xie, Min ^a   Bagella, Luigi ^c   Giordano, Antonio ^c   Michael, Lloyd H ^a   DeMayo, Francesco J ^a   Schneider, Michael D ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^c TEMPLE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN; CYCLIN DEPENDENT KINASE 7; CYCLIN DEPENDENT KINASE 9; CYCLIN T1; ENDOTHELIN; RNA POLYMERASE II; SMALL NUCLEAR RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HEART DEVELOPMENT; HEART DISEASE; HEART VENTRICLE HYPERTROPHY; MECHANICAL STRESS; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN DOMAIN; RNA ANALYSIS; SIGNAL TRANSDUCTION;

NON-PROGRAMMATIC;

ANIMALS; BASE SEQUENCE; CARDIOMEGALY; CELL LINE; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE 9; CYCLIN-DEPENDENT KINASES; CYCLINS; DNA; HUMANS; MICE; MOLECULAR SEQUENCE DATA; RATS; RATS, SPRAGUE-DAWLEY; RNA;

ANIMALIA;

EID: 0036851825     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm778     Document Type: Article

References (45)

1. Sadoshima, J. & Izumo, S. The cellular and molecular response of cardiac myocytes to mechanical stress. Annu. Rev. Physiol. 59, 551-571 (1997).
2. MacLellan, W.R. & Schneider, M.D. Genetic dissection of cardiac growth control pathways. Annu. Rev. Physiol. 62, 289-320 (2000).
3. Verdecchia, P. et al. Left ventricular mass and cardiovascular morbidity in essential hypertension: The MAVI study. J. Am. Coll. Cardiol. 38, 1829-1835 (2001).
4. Mathew, J. et al. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation 104, 1615-1621 (2001).
5. Esposito, G. et al. Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress. Circulation 105, 85-92 (2002).
6. Sano, M. & Schneider, M.D. Still stressed out but doing fine: Normalization of wall stress is superfluous to maintaining cardiac function in chronic pressure overload. Circulation 105, 8-10 (2002).
7. McKinsey, T.A. & Olson, E.N. Cardiac hypertrophy: Sorting out the circuitry. Curr. Opin. Genet. Develop. 9, 267-274 (1999).
8. Molkentin, J.D. & Dorn, G.W., 2nd. Cytoplasmic signaling pathways that regulate cardiac hypertrophy. Annu. Rev. Physiol. 63, 391-426 (2001).
9. Molkentin, J.D. et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 93, 215-228 (1998).
10. Adams, J.W. et al. Enhanced Gαq signaling: A common pathway mediates cardiac hypertrophy and apoptotic heart failure. Proc. Natl. Acad. Sci. USA 95, 10140-10145 (1998).
11. Zhang, D. et al. TAK1 is activated in the myocardium after pressure overload and is sufficient to provoke heart failure in transgenic mice. Nat. Med. 6, 556-563 (2000).
12. Shioi, T. et al. The conserved phosphoinositide 3-kinase pathway determines heart size in mice. EMBO J. 19, 2537-2548 (2000).
13. Bueno, O.F. et al. The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J. 19, 6341-6350 (2000).
14. Minamino, T. et al. MEKK1 is essential for cardiac hypertrophy and dysfunction induced by Gq. Proc. Natl. Acad. Sci. USA 99, 3866-3871 (2002).
15. Antos, C.L. et al. Activated glycogen synthase-3 β suppresses cardiac hypertrophy in vivo. Proc. Natl. Acad. Sci. USA 99, 907-912 (2002).
16. Oh, H. et al. Telomerase reverse transcriptase promotes cardiac muscle cell proliferation, hypertrophy, and survival. Proc. Natl. Acad. Sci. USA 98, 10308-10313 (2001).
17. Shioi, T. et al. Akt/protein kinase B promotes organ growth in transgenic mice. Mol. Cell. Biol. 22, 2799-2809, (2002).
18. Dahmus, M.E. Reversible phosphorylation of the C-terminal domain of RNA polymerase II. J. Biol. Chem. 271, 19009-19012 (1996).
19. Akhtar, A., Faye, G. & Bentley, D.L. Distinct activated and non-activated RNA polymerase II complexes in yeast. EMBO J. 15, 4654-4664, (1996).
20. Cho, H. et al. A protein phosphatase functions to recycle RNA polymerase II. Genes Dev. 13, 1540-1552 (1999).
21. Orphanides, G. & Reinberg, D. A unified theory of gene expression. Cell 108, 439-451 (2002).
22. Majello, B. & Napolitano, G. Control of RNA polymerase II activity by dedicated CTD kinases and phosphatases. Front. Biosci. 6, D1358-1368 (2001).
23. Abdellatif, M. et al. A Ras-dependent pathway regulates RNA polymerase II phosphorylation in cardiac myocytes: Implications for cardiac hypertrophy. Mol. Cell. Biol. 18, 6729-6736 (1998).
24. De Luca, A. et al. Cyclin T2a gene maps on human chromosome 2q21. J. Histochem. Cytochem. 49, 693-698 (2001).
25. Kwak, Y.T., Ivanov, D., Guo, J., Nee, E. & Gaynor, R.B. Role of the human and murine cyclin T proteins in regulating HIV-1 tat-activation. J. Mol. Biol. 288, 57-69 (1999).
26. Wimmer, J. et al. Interactions between Tat and TAR and human immunodeficiency virus replication are facilitated by human cyclin T1 but not cyclins T2a or T2b. Virology 255, 182-189 (1999).
27. Peng, J., Zhu, Y., Milton, J.T. & Price, D.H. Identification of multiple cyclin subunits of human P-TEFb. Genes Dev. 12, 755-762 (1998).
28. Dorn, G.W. & Brown, J.H. Gq signaling in cardiac adaptation and maladaptation. Trends Cardiovasc. Med. 9, 26-34 (1999).
29. Doi, T., Sugimoto, H., Arimoto, I., Hiroaki, Y. & Fujiyoshi, Y. Interactions of endothelin receptor subtypes A and B with Gi, Go, and Gq in reconstituted phospholipid vesicles. Biochemistry 38, 3090-3099 (1999).
30. Taigen, T., De Windt, L.J., Lim, H.W. & Molkentin, J.D. Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy. Proc. Natl. Acad. Sci. USA 97, 1196-1201 (2000).
31. Asakura, M. et al. Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: Metalloproteinase inhibitors as a new therapy. Nature Med. 8, 35-40, (2002).
32. Zhou, M. et al. Tat modifies the activity of CDK9 to phosphorylate serine 5 of the RNA polymerase II carboxyl-terminal domain during human immunodeficiency virus type 1 transcription. Mol. Cell. Biol. 20, 5077-5086 (2000).
33. Patturajan, M, et al. Growth-related changes in phosphorylation of yeast RNA polymerase II. J. Biol. Chem. 273, 4689-4694, (1998).
34. Herrmann, C.H. & Mancini, M.A. The Cdk9 and cyclin T subunits of TAK/P-TEFb localize to splicing factor-rich nuclear speckle regions. J. Cell. Sci. 114, 1491-1503, (2001).
35. Zhu, Y. et al. Transcription elongation factor P-TEFb is required for HIV-1 tat transactivation in vitro. Genes Dev. 11, 2622-2632 (1997).
36. Yang, Z., Zhu, Q., Luo, K. & Zhou, Q. The 7SK small nuclear RNA inhibits the CDK9/cyclin T1 kinase to control transcription. Nature 414, 317-322 (2001).
37. Nguyen, V.T., Kiss, T., Michels, A.A. & Bensaude, O. 7SK small nuclear RNA binds to and inhibits the activity of CDK9/cyclin T complexes. Nature 414, 322-325 (2001).
38. Gaussin, V. et al. Endocardial cushion and myocardial defects after cardiac myocyte-specific conditional deletion of the bone morphogenetic protein receptor ALK3. Proc. Natl. Acad. Sci. USA 99, 2878-2883 (2002).
39. Wada, T. et al. FACT relieves DSIF/NELF-mediated inhibition of transcriptional elongation and reveals functional differences between P-TEFb and TFIIH. Mol. Cell 5, 1067-1072 (2000).
40. Chao, S.H. & Price, D.H. Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J. Biol. Chem. 276, 31793-31799, (2001).
41. Yang, X., Herrmann, C.H. & Rice, A.P. The human immunodeficiency virus Tat proteins specifically associate with TAK in vivo and require the carboxyl-terminal domain of RNA polymerase II for function. J. Virol. 70, 4576-4584 (1996).
42. Subramaniam, A. et al. Tissue-specific regulation of the alpha-myosin heavy chain gene promoter in transgenic mice. J. Biol. Chem. 266, 24613-24620 (1991).
43. He, T.C. et al. A simplified system for generating recombinant adenoviruses. Proc. Natl. Acad. Sci. USA 95, 2509-2514 (1998).
44. Matsuoka, M., Kato, J.Y., Fisher, R.P., Morgan, D.O. & Sherr, C.J. Activation of cyclin-dependent kinase 4 (cdk4) by mouse MO15-associated kinase. Mol. Cell. Biol. 14, 7265-7275 (1994).
45. de Falco, G. et al. Physical interaction between CDK9 and B-Myb results in suppression of B-Myb gene autoregulation. Oncogene 19, 373-379 (2000).